Voyager Therapeutics (NASDAQ:VYGR – Get Free Report) and Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations and institutional ownership.
Volatility & Risk
Voyager Therapeutics has a beta of 1.32, suggesting that its stock price is 32% more volatile than the S&P 500. Comparatively, Agios Pharmaceuticals has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500.
Valuation & Earnings
This table compares Voyager Therapeutics and Agios Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Voyager Therapeutics | $34.46 million | 4.80 | -$119.72 million | ($1.80) | -1.49 |
| Agios Pharmaceuticals | $54.03 million | 37.18 | -$412.78 million | ($7.01) | -4.80 |
Voyager Therapeutics has higher earnings, but lower revenue than Agios Pharmaceuticals. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of recent recommendations and price targets for Voyager Therapeutics and Agios Pharmaceuticals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Voyager Therapeutics | 1 | 0 | 2 | 1 | 2.75 |
| Agios Pharmaceuticals | 1 | 4 | 5 | 1 | 2.55 |
Voyager Therapeutics presently has a consensus target price of $16.50, suggesting a potential upside of 514.53%. Agios Pharmaceuticals has a consensus target price of $41.75, suggesting a potential upside of 24.07%. Given Voyager Therapeutics’ stronger consensus rating and higher possible upside, research analysts clearly believe Voyager Therapeutics is more favorable than Agios Pharmaceuticals.
Insider & Institutional Ownership
48.0% of Voyager Therapeutics shares are owned by institutional investors. 12.7% of Voyager Therapeutics shares are owned by company insiders. Comparatively, 5.4% of Agios Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Profitability
This table compares Voyager Therapeutics and Agios Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Voyager Therapeutics | -312.63% | -57.92% | -45.00% |
| Agios Pharmaceuticals | -418.24% | -35.67% | -33.06% |
Summary
Voyager Therapeutics beats Agios Pharmaceuticals on 9 of the 14 factors compared between the two stocks.
About Voyager Therapeutics
Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
